[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-181126114--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-181126114","PRESSRELEASE"," Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery","2026-11-18T16:06:25.000+01:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> \n11,000+ Target Proteins. Reliable Supply. Built for AI-Driven Discovery.\u003C\u002Fp>\u003Cp> HOUSTON, Nov. 18, 2026 \u002FPRNewswire\u002F -- As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development, access to well-characterized target proteins is essential for evaluating AI-designed molecules. Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global biotechnology company specializing in recombinant proteins, antibodies, and CRO services, introduces two dedicated target protein collections for AI-driven discovery: AI-Trusted Proteins and AI-Qualified \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.sinobiological.com\u002Fcategory\u002Fsolutions\u002Faidd-targets?utm_source=press-release&utm_medium=word&utm_campaign=2611-news-aidd-sol-target\">Proteins.\u003C\u002Fa>\u003C\u002Fp>\u003Cp> \n    \n                \n                    \n                \n    \nTwo Collections. Two Ways to Support AI Validation.\u003C\u002Fp>\u003Cp> AI-Trusted Proteins — Proven in AI Research\u003C\u002Fp>\u003Cp> AI-Trusted Proteins have been used in AI-focused company validation projects, with some proteins featured in published research. This collection currently covers 600+ targets and 960+ individual proteins, with available characterization data for each protein potentially including SPR, BLI, ELISA, cell-based activity assays, SEC-HPLC, and SEC-MALS analyses.\u003C\u002Fp>\u003Cp> AI-Qualified Proteins — Characterized for AI Validation\u003C\u002Fp>\u003Cp> AI-Qualified Proteins feature experimentally characterized target binding activity, including SPR\u002FBLI validation data, as well as specialized formats such as biotinylated proteins for AI-driven research. With 680+ targets and 1,700+ individual proteins, this collection provides researchers with a broad selection of characterized target proteins for evaluating AI-designed molecules.\u003C\u002Fp>\u003Cp> The 4S System: Building Confidence in Target Protein Resources\u003C\u002Fp>\u003Cp> Supporting these collections is Sino Biological's 4S System — Scale, Scope, Speed, and Supply. This system provides over 11,000 recombinant target proteins, broad target coverage, diverse protein formats, and reliable long-term supply to support AI-driven research programs.\u003C\u002Fp>\u003Cp> Sino Biological has also developed a therapeutic target directory covering 12 therapeutic areas and more than 100 diseases, enabling researchers to explore relevant targets by therapeutic area or disease.\u003C\u002Fp>\u003Cp> 4RISE™: Connecting Target Resources with End-to-End AI Validation\u003C\u002Fp>\u003Cp> As a key resource within Sino Biological's 4RISE™ AI Lab Validation Solution, the AI-focused target protein library works alongside high-throughput protein expression, binding and affinity characterization, developability assessment, and functional validation.\u003C\u002Fp>\u003Cp> Built around four strengths — Rapid, In-Depth, Seamless, and Empirical — 4RISE™ provides integrated wet-lab support to help researchers advance AI-designed molecules from computational predictions to experimental evidence.\u003C\u002Fp>\u003Cp> \"AI-driven discovery depends on reliable experimental resources to evaluate designed molecules and guide subsequent research decisions,\" said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. \"By combining AI-Trusted and AI-Qualified target proteins with our 4S System, we aim to provide researchers with well-characterized target resources, broad coverage, and dependable supply to support AI-driven protein and antibody discovery.\"\u003C\u002Fp>\u003Cp> Sino Biological, \u003Ca target=\"_blank\" href=\"mailto:gmo@sinobiological.cn\">Inc.gmo@sinobiological.cn\u003C\u002Fa> \u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.sinobiological.com\u002F\">www.sinobiological.com\u003C\u002Fa>\u003C\u002Fp>\u003Cp> \u003C\u002Fp>\u003Cp> \u003C\u002Fp>\u003Cp>  View original content to download multimedia:https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002Fsino-biological-introduces-ai-trusted-and-qualified-target-protein-collections-for-ai-driven-discovery-302943195.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","11,000+ Target Proteins. Reliable Supply. Built for AI-Driven Discovery. HOUSTON, Nov. 18, 2026 \u002FPRNewswire\u002F -- As AI accelerates recombinant protein and antibo",[16,21,22,27,32,37,41,46,51,56],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-181126122"," Synthesys kondigt samenwerking met WisdomTree aan na registratie van drie getokeniseerde fondsen in Singapore","2026-11-18T16:36:25.000+01:00","Synthesys Network zal gereguleerde tussenpersonen toegang bieden tot de portefeuille van getokeniseerde fondsen van WisdomTree, te beginnen met drie fondsen die",{"id":4,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":11,"orgId":13,"description":14},{"id":23,"title":24,"pubDate":25,"logoUrl":8,"thirdParty":11,"orgId":13,"description":26},"CSN-181126113"," FP Markets Adds Anthropic Share CFD to Product Range","2026-11-18T16:04:25.000+01:00","FP Markets enhances its Share CFD offering – Anthropic trading goes live on 19 November 2026 for clients worldwide. LIMASSOL, Cyprus, Nov. 18, 2026 \u002FPRNewswire\u002F",{"id":28,"title":29,"pubDate":30,"logoUrl":8,"thirdParty":11,"orgId":13,"description":31},"CSN-181126098"," AI Inspo Unveils an All-in-One AI Social Media Agent","2026-11-18T15:01:24.000+01:00","Personalised strategy, content creation, publishing and performance analysis in one platform A Connected Workflow for Social Media Teams SAN FRANCISCO, Nov. 18,",{"id":33,"title":34,"pubDate":35,"logoUrl":8,"thirdParty":11,"orgId":13,"description":36},"CSN-181126091"," New Diagnostic Radiology from Hyland Meets Growing Demand for Medical Image Reading and Management with Intelligent, Scalable Workflows","2026-11-18T14:31:25.000+01:00","- Imaging demand is projected to rise approximately 17% for MRI and 25% for CT by 2055, even as the radiologist workforce is projected to reach only 90% of need",{"id":38,"title":39,"pubDate":35,"logoUrl":8,"thirdParty":11,"orgId":13,"description":40},"CSN-181126090"," ACTO AI Roleplay Integration with Veeva Vault CRM via X-Pages Now Available for Field Teams to Rehearse Each HCP Conversation Before It Happens","Sales reps and MSLs can launch ACTO CxZone with one click from their planning screens, practice with an HCP avatar grounded in MLR-approved Veeva Vault content,",{"id":42,"title":43,"pubDate":44,"logoUrl":8,"thirdParty":11,"orgId":13,"description":45},"CSN-181126087"," Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach","2026-11-18T14:24:25.000+01:00","- EC approval follows recent U.S. FDA approval of Biocon's pertuzumab biosimilar - Provides an additional treatment option for patients with HER2-positive breas",{"id":47,"title":48,"pubDate":49,"logoUrl":8,"thirdParty":11,"orgId":13,"description":50},"CSN-181126068"," Dr. Robin Zeng Highlights Innovation and Cooperation at 2026 APEC CEO Summit","2026-11-18T13:32:25.000+01:00","SHENZHEN, China, Nov. 18, 2026 \u002FPRNewswire\u002F -- Dr. Robin Zeng, founder, chairman and CEO of CATL, participated in the opening business dialogue at the 2026 APEC",{"id":52,"title":53,"pubDate":54,"logoUrl":8,"thirdParty":11,"orgId":13,"description":55},"CSN-181126044"," Berlin Heals Initiates International Randomized, Double-Blind, Sham-Controlled C-MIC IV Trial","2026-11-18T11:07:25.000+01:00","News provided by Berlin Heals Holding AG ZUG, Switzerland, Nov. 18, 2026 \u002FPRNewswire\u002F -- Berlin Heals Holding AG, a clinical-stage medical device company develo",{"id":57,"title":58,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":60},"CSN-181126042"," New global dataset maps where mining and metals intersect with biodiversity","2026-11-18T11:01:25.000+01:00","Risks and opportunities for biodiversity and business are unevenly distributed across a relatively small number of locations, according to the first analysis of"]